Pfizer Inc. (NYSE:PFE) Shares Sold by Burns J W & Co. Inc. NY

Share on StockTwits

Burns J W & Co. Inc. NY lessened its stake in Pfizer Inc. (NYSE:PFE) by 0.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 87,702 shares of the biopharmaceutical company’s stock after selling 486 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Pfizer were worth $3,151,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Murphy Capital Management Inc. grew its holdings in shares of Pfizer by 2.8% in the third quarter. Murphy Capital Management Inc. now owns 57,612 shares of the biopharmaceutical company’s stock valued at $2,070,000 after purchasing an additional 1,589 shares during the period. Domani Wealth LLC grew its position in shares of Pfizer by 5.9% during the third quarter. Domani Wealth LLC now owns 5,579 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 310 shares during the last quarter. Carlton Hofferkamp & Jenks Wealth Management LLC grew its position in shares of Pfizer by 1.4% during the third quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 61,425 shares of the biopharmaceutical company’s stock worth $2,198,000 after acquiring an additional 856 shares during the last quarter. Larson Financial Group LLC grew its position in shares of Pfizer by 28.1% during the third quarter. Larson Financial Group LLC now owns 6,675 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 1,463 shares during the last quarter. Finally, Community Trust & Investment Co. grew its position in shares of Pfizer by 44.5% during the third quarter. Community Trust & Investment Co. now owns 187,149 shares of the biopharmaceutical company’s stock worth $6,724,000 after acquiring an additional 57,634 shares during the last quarter. 71.69% of the stock is owned by institutional investors.

A number of equities analysts have recently issued reports on the stock. Goldman Sachs Group restated a “buy” rating and set a $49.00 target price on shares of Pfizer in a research report on Monday, June 17th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. Morgan Stanley lowered their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 27th. Finally, Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. Twelve investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average target price of $45.20.

In other news, Director Scott Gottlieb purchased 3,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average price of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $104,160. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were bought at an average price of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Pfizer stock traded up $0.41 during midday trading on Friday, reaching $36.20. The company’s stock had a trading volume of 9,263,194 shares, compared to its average volume of 19,407,336. Pfizer Inc. has a fifty-two week low of $33.97 and a fifty-two week high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock’s 50 day simple moving average is $35.94 and its 200 day simple moving average is $39.97. The firm has a market capitalization of $195.97 billion, a PE ratio of 12.07, a P/E/G ratio of 2.82 and a beta of 0.66.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business’s revenue was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.77 EPS. Equities analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a dividend yield of 3.98%. The ex-dividend date is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Recession

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.